Home / Market News / $LEGN
benzinga Corporate Catalyst Impact 55/100 ● negative

JP Morgan Maintains Neutral on Legend Biotech, Lowers Price Target to $33

Oct 9, 2026, 8:01 PM UTC · Primary ticker $LEGN

JP Morgan analyst Jessica Fye maintained a Neutral rating on Legend Biotech but lowered its price target from $35 to $33. This indicates a slightly less optimistic outlook from the analyst, which could lead to minor downward pressure on the stock in the short term.

JP Morgan analyst Jessica Fye has reiterated a 'Neutral' rating on Legend Biotech (LEGN) but reduced the price target from $35 to $33. This adjustment reflects a slightly diminished valuation outlook from a prominent financial institution. While the 'Neutral' rating suggests no strong conviction for either significant upside or downside, the lowered price target could signal concerns about near-term growth prospects or valuation multiples. This news primarily affects Legend Biotech, potentially leading to a minor negative reaction in its stock price as investors digest the analyst's revised expectations. In the short term, this could create some selling pressure, but the long-term implications depend on the company's fundamental performance and future pipeline developments. For traders, the key risk is a potential dip in LEGN's stock price following the news, while an opportunity might arise for those looking to buy on a minor dip if they believe the analyst's revised target is overly conservative.

$LEGN negative Price target lowered by analyst
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.